Centessa Pharmaceuticals (NASDAQ:CNTA) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Centessa Pharmaceuticals (NASDAQ:CNTA) announced its earnings results on Tuesday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02), Zacks reports.

Centessa Pharmaceuticals Stock Up 6.7 %

Shares of CNTA stock traded up $0.84 during trading on Thursday, hitting $13.44. 437,153 shares of the company were exchanged, compared to its average volume of 309,101. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.37 and a current ratio of 10.37. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -8.87 and a beta of 1.40. The business’s 50-day simple moving average is $9.72 and its 200 day simple moving average is $9.86. Centessa Pharmaceuticals has a twelve month low of $5.15 and a twelve month high of $13.56.

Analysts Set New Price Targets

A number of brokerages have weighed in on CNTA. Oppenheimer reissued an “outperform” rating and issued a $14.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday. Morgan Stanley lifted their price target on shares of Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Friday, June 21st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.